Home > Updates > Research and Industry News > Luxturna, the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene, recommended for approval by the European Medicines Agency
Luxturna, the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene, recommended for approval by the European Medicines Agency